Disclosed positions

Estimated from their latest filings — positions may have changed since

$3.34M

combined est. value

Stock	Shares	Price	Value	Weight	As of
ORICOric Pharmaceuticals, Inc.	254,872	$8.56	$2.18M	65%	2026-01-16
ELVNEnliven Therapeutics, Inc.	22,647	$50.92	$1.15M	35%	2026-02-17

ORIC

Oric Pharmaceuticals, Inc.

$2.18M

254,872 sh

ELVN

Enliven Therapeutics, Inc.

$1.15M

22,647 sh

All filings on record

Every Form 4 transaction we track for this filer

all 10buys 0sells 8

Stock	Transaction	Date	~6mo later
ELVNEnliven Therapeutics, Inc.	Sell $32.2K · 1,230 sh	2026-02-17	—
ELVNEnliven Therapeutics, Inc.	Sell $19.4K · 718 sh	2026-01-20	—
ELVNEnliven Therapeutics, Inc.	Sell $13.5K · 512 sh	2026-01-20	—
ORICOric Pharmaceuticals, Inc.	Sell $38.4K · 3,200 sh	2026-01-16	—
ORICOric Pharmaceuticals, Inc.	Sell $42.0K · 3,500 sh	2026-01-16	—
ELVNEnliven Therapeutics, Inc.	Sell $107.1K · 4,285 sh	2026-01-09	—
ELVNEnliven Therapeutics, Inc.	Sell $200.7K · 8,015 sh	2026-01-08	—
ELVNEnliven Therapeutics, Inc.	Sell $40.5K · 1,620 sh	2026-01-08	—
ORICOric Pharmaceuticals, Inc.	Exercise $5.4K · 1,447 sh	2025-10-03	—
ORICOric Pharmaceuticals, Inc.	Exercise $50.2K · 31,353 sh	2025-10-03	—

ELVNSell

2026-02-17 · Enliven Therapeutics, Inc.

$32.2K

—

ELVNSell

2026-01-20 · Enliven Therapeutics, Inc.

$19.4K

—

ELVNSell

2026-01-20 · Enliven Therapeutics, Inc.

$13.5K

—

ORICSell

2026-01-16 · Oric Pharmaceuticals, Inc.

$38.4K

—

ORICSell

2026-01-16 · Oric Pharmaceuticals, Inc.

$42.0K

—

ELVNSell

2026-01-09 · Enliven Therapeutics, Inc.

$107.1K

—

ELVNSell

2026-01-08 · Enliven Therapeutics, Inc.

$200.7K

—

ELVNSell

2026-01-08 · Enliven Therapeutics, Inc.

$40.5K

—

ORICExercise

2025-10-03 · Oric Pharmaceuticals, Inc.

$5.4K

—

ORICExercise

2025-10-03 · Oric Pharmaceuticals, Inc.

$50.2K

—

Outcomes measure each disclosed buy against the closing price ~6 months (120 trading days) later, with the S&P 500 over the same span for context. Pre-scheduled 10b5-1 plan trades are excluded from the record. Positions are estimated from the latest reported post-transaction holdings, split-adjusted, at the latest close. Built from SEC Form 4 filings and market prices — past outcomes, not predictions or advice.